A hospital-associated fungus that can shrug off nearly every antifungal medication doctors have is turning up in nearly half of US states this year. It sounds alarming, and in the settings where it spreads, it genuinely can be — but the latest CDC data tells a more specific, less dramatic story than “spreading rapidly” headlines might suggest.
Key Takeaways
- As of July 18, the CDC has recorded 3,130 cases of Candida auris across 23 states in 2026 — Texas (706), Michigan (503), and Illinois (366) have the most.
- This year’s case count is essentially flat compared to the same point last year (3,348 cases), and the CDC says the annual growth rate has actually been slowing since 2022.
- More than 95% of samples tested were resistant to fluconazole, the usual first-line antifungal, though most infections can still be treated with a different drug class called echinocandins.
- Healthy people with no healthcare exposure are not considered at meaningful risk — the danger is concentrated in hospitals and long-term care facilities, especially among patients with catheters, breathing tubes, or other invasive devices.
What Candida Auris Actually Is
C. auris is a yeast, first identified in Japan in 2009 and first reported in the US in 2016, that spreads easily among sick patients in healthcare settings. It can cause a range of infections, from relatively mild skin infections to severe, life-threatening bloodstream infections. What makes it a particular concern for hospitals is durability and drug resistance: it can survive on surfaces like doorknobs and bedrails for extended periods, and some strains resist nearly every antifungal medication available. A CDC analysis of over 8,000 samples from 2022-2023 found more than 95% were resistant to fluconazole, the typical first-choice treatment, while 15% resisted amphotericin B and about 1% resisted echinocandins — the drug class that still works against most infections. Fewer than 1% of samples were resistant to all three drug classes at once, though even that small fraction represents infections doctors currently have very limited options to treat.
Why the Case Numbers Aren’t Actually Accelerating
Despite the headline-grabbing “23 states” figure, the CDC’s own data shows this year’s case count is essentially unchanged from last year at this point (3,130 vs. 3,348), and the agency states plainly that while cases have risen every year since C. auris first emerged, the rate of that annual increase has been slowing since 2022. That’s a meaningfully different story than several headlines this week suggesting the fungus is “spreading rapidly” or “on the move” — the more accurate read of the CDC’s own numbers is that detection remains elevated and geographically widespread, but growth has leveled off rather than accelerated.
Who’s Actually at Risk
According to the CDC, most healthy people without healthcare exposure don’t need to worry about C. auris. The real risk is concentrated among hospital and nursing home patients, particularly those with invasive medical devices like catheters or breathing tubes, and people who are already immunocompromised. A review of cases from 2022-2024 found about 88% occurred in people over age 45, with the majority in men, and mostly in acute care settings. Because most people who contract C. auris are already seriously ill with other conditions, the CDC notes it can be difficult to determine exactly how much the fungus itself contributes when a patient dies — reported mortality estimates range widely, from roughly 30% to 60%, largely because the data comes from a limited number of patients who were often critically ill to begin with.
What Healthcare Facilities Are Doing About It
Standard infection-control measures — thorough hand hygiene, gowns and gloves for patient care, disinfecting shared equipment and rooms, clear signage identifying affected patients, and communication when transferring patients between facilities — remain the primary defense, and the CDC notes these measures have successfully limited spread in some areas when implemented early. For the general public, there’s no specific action needed; this is fundamentally a healthcare-setting issue rather than a community health threat.
Sources: CDC, Tracking C. auris (2026 surveillance data); ABC News, “Cases of potentially deadly fungus detected in 23 states, CDC data shows” (Aug. 5, 2026); Healthline, “Drug-Resistant ‘Superbug’ Confirmed in 23 States: Should You Worry?” (Aug. 2026).